V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160014393 | 160007064 | 1.72 | 65.5 | Neo-adjuvant (N) | 2018-02-19 | 2018-03-05 | Liposomal Doxorubicin (Caelyx) | N | N | DOXORUBICIN | 101626676 |
| 160014394 | 160007065 | 1.63 | 88 | Adjuvant (A) | 2016-12-01 | 2016-12-02 | Doxorubicin + Ifosfamide | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100886520 |
| 160014396 | 160007066 | 1.67 | 71.3 | Palliative (P) | 2017-07-13 | 2017-07-14 | Cisplatin + Pemetrexed | 01 | Y | CISPLATIN + PEMETREXED | 100197521 |
| 160014398 | 160007067 | 1.74 | 86 | Palliative (P) | 2017-08-04 | 2017-08-19 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101426494 |
| 160014399 | 160007068 | 1.73 | 65.3 | Palliative (P) | 2019-09-02 | 2019-09-16 | Cisplatin + Pemetrexed | 2 | N | CISPLATIN + PEMETREXED | 100308590 |
| 160014400 | 160007069 | 1.74 | 80.9 | Curative (C) | null | 2018-09-25 | Cisplatin + Pemetrexed | null | N | CISPLATIN + PEMETREXED | 101317078 |
| 160014401 | 160007070 | 1.56 | 58.55 | Adjuvant (A) | 2017-04-25 | 2017-04-27 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 100268229 |
| 160014405 | 160007071 | 1.75 | 66 | Curative (C) | 2017-12-15 | 2017-12-23 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 101068634 |
| 160014406 | 160007072 | 1.72 | 86 | Palliative (P) | 2016-09-07 | 2016-09-17 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 101502177 |
| 160014408 | 160007073 | 1.7 | 89 | Palliative (P) | 2017-06-06 | 2017-06-29 | Dactinomycin + Vincristine | 02 | N | DOXORUBICIN + OLARATUMAB | 101474985 |
| 160014412 | 160007074 | 1.76 | 63.4 | Palliative (P) | 2016-04-20 | 2016-05-03 | Gemcitabine day 1&8 | 01 | N | CISPLATIN + VINORELBINE | 100299080 |
| 160014413 | 160007075 | 1.82 | 88.6 | Neo-adjuvant (N) | 2019-12-25 | 2020-01-02 | Cisplatin + Pemetrexed | 2 | N | CISPLATIN + PEMETREXED | 101260531 |
| 160014416 | 160007076 | 1.76 | 82.5 | Palliative (P) | 2019-03-31 | 2019-04-11 | ETOPOSIDE + RITUXIMAB | 02 | N | IBRUTINIB | 101631375 |
| 160014417 | 160007077 | 1.67 | 67.6 | Palliative (P) | 2019-09-19 | 2019-10-08 | DOXORUBICIN | 02 | N | DOXORUBICIN | 100393948 |
| 160014418 | 160007078 | 1.67 | 86.3 | Palliative (P) | 2017-07-18 | 2017-07-18 | Cisplatin + Pemetrexed | 02 | Y | CISPLATIN + PEMETREXED | 101182493 |
| 160014421 | 160007079 | 1.75 | 82 | Palliative (P) | 2019-09-06 | 2019-09-06 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 100756811 |
| 160014422 | 160007080 | 1.8 | 60.15 | Palliative (P) | 2017-06-08 | 2017-06-28 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101648146 |
| 160014423 | 160007081 | 1.7 | 65.1 | Palliative (P) | 2018-01-15 | 2018-01-19 | Carboplatin + Paclitaxel (3 weekly) | 02 | N | CARBOPLATIN + PACLITAXEL | 100755606 |
| 160014424 | 160007082 | 1.74 | 60 | Palliative (P) | 2016-03-03 | 2016-03-15 | Trial Unspecified | 02 | N | IMATINIB | 100340340 |
| 160014425 | 160007083 | null | null | Palliative (P) | 2019-09-25 | 2019-10-09 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 100462746 |
| 160014431 | 160007085 | 1.76 | 75 | null | 2017-11-15 | 2017-11-29 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100259693 |
| 160014433 | 160007086 | 1.73 | 89 | Neo-adjuvant (N) | 2019-12-17 | 2019-12-18 | NB Low/Interm risk guidelines Carbo/Etop | 02 | N | TRIAL | 100703169 |
| 160014436 | 160007087 | 1.5 | 87.3 | Palliative (P) | 2017-09-10 | 2017-09-28 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 100511387 |
| 160014442 | 160007088 | null | null | Neo-adjuvant (N) | 2019-11-29 | 2019-11-29 | DABRAFENIB + TRAMETINIB | 02 | null | LENVATINIB | 101369651 |
| 160014443 | 160007089 | 1.74 | 84.1 | null | 2016-08-15 | 2016-08-15 | Trabectedin | 02 | Y | EW EUROEWING 2012 ARM B VDC | 100386173 |
| 160014444 | 160007090 | 1.65 | 70 | Palliative (P) | 2017-05-07 | 2017-05-17 | Liposomal Doxorubicin (Caelyx) | N | N | CARBOPLATIN + PACLITAXEL | 100419210 |
| 160014446 | 160007091 | 1.52 | 105.4 | Palliative (P) | 2016-02-11 | 2016-02-11 | Pemetrexed | 02 | N | TRIAL UNSPECIFIED | 101650872 |
| 160014449 | 160007093 | 1.75 | 77.7 | Curative (C) | 2018-03-10 | 2018-03-20 | Doxorubicin + Ifosfamide | N | N | DOXORUBICIN + IFOSFAMIDE | 101227159 |
| 160014450 | 160007094 | 1.75 | 55 | Palliative (P) | 2019-01-08 | 2019-01-16 | Doxorubicin 75mg/m2 | 02 | N | CISPLATIN | 100296625 |
| 160014451 | 160007095 | 1.55 | 86 | Palliative (P) | 2019-11-09 | 2019-11-17 | Epirubicin (weekly) | 02 | null | DOXORUBICIN | 100601989 |
| 160014452 | 160007096 | 1.69 | 90 | Palliative (P) | 2017-11-26 | 2017-11-27 | CARBOPLATIN + PACLITAXEL | 02 | N | CARBOPLATIN + PACLITAXEL | 101791412 |
| 160014453 | 160007097 | 1.65 | 70.9 | Palliative (P) | 2017-04-26 | 2017-05-10 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100230821 |
| 160014454 | 160007098 | 1.71 | 107 | Neo-adjuvant (N) | 2019-02-16 | 2019-02-16 | null | N | N | CISPLATIN + GEMCITABINE | 100364041 |
| 160014455 | 160007099 | 1.78 | 106.7 | Palliative (P) | null | 2018-11-22 | Epirubicin (weekly) | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVA | 101269704 |
| 160014457 | 160007100 | 1.71 | 77 | Curative (C) | 2019-08-14 | 2019-08-14 | Liposomal Doxorubicin (Caelyx) | 02 | N | DOXORUBICIN + ETOPOSIDE + IFOSFAMIDE + VINCRISTINE | 100472594 |
| 160014458 | 160007101 | 1.66 | 80 | Palliative (P) | 2018-10-24 | 2018-11-20 | Cisplatin + Pemetrexed | 01 | N | CISPLATIN + PEMETREXED | 100780079 |
| 160014459 | 160007102 | 1.76 | 63.3 | Palliative (P) | 2017-07-11 | 2017-07-11 | null | 02 | N | LIPOSOMAL DOXORUBICIN | 100533201 |
| 160014461 | 160007103 | 1.58 | 54 | 03 | null | 2016-04-08 | CARBOPLATIN + PACLITAXEL | 02 | N | CARBOPLATIN + PACLITAXEL | 101530149 |
| 160014462 | 160007104 | 1.56 | 72 | null | 2018-07-08 | 2018-07-14 | BEVACIZUMAB + CARBO + PACLITAXEL | 02 | Y | DOXORUBICIN + OLARATUMAB | 101554898 |
| 160014463 | 160007105 | 1.57 | 98 | Neo-adjuvant (N) | 2019-12-07 | 2019-12-11 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101677549 |
| 160014464 | 160007106 | 1.8 | 52 | Palliative (P) | 2018-01-05 | 2018-01-05 | Doxorubicin + Olaratumab | 02 | N | EW EUROEWING 2012 ARM B VDC | 101715424 |
| 160014466 | 160007107 | 1.82 | 57.5 | Palliative (P) | 2019-07-11 | 2019-07-29 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100704476 |
| 160014468 | 160007108 | 1.56 | 76 | Curative (C) | 2019-08-14 | 2019-08-29 | VINCRISTINE | 02 | N | CARBOPLATIN + PACLITAXEL | 101080742 |
| 160014471 | 160007109 | 1.68 | 61 | Neo-adjuvant (N) | 2019-11-25 | 2019-11-25 | Ixazomib + Lenalidomide | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101233199 |
| 160014474 | 160007110 | 1.82 | 62 | null | 2020-09-09 | 2020-09-10 | VIDE | 02 | N | DACTINOMYCIN + DOXORUBICIN + IFOSFAMIDE + VINCRISTINE | 100567955 |
| 160014477 | 160007111 | 1.77 | 51 | Palliative (P) | 2019-03-06 | 2019-03-11 | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + VINCRISTINE | 02 | N | TRIAL | 101562164 |
| 160014483 | 160007112 | 1.54 | 84 | Palliative (P) | 2019-08-07 | 2019-08-07 | DOCETAXEL + GEMCITABINE | 2 | N | DOXORUBICIN + OLARATUMAB | 101100371 |
| 160014486 | 160007113 | 1.71 | 66.5 | null | null | 2018-04-15 | Cisplatin + Pemetrexed | N | Y | CISPLATIN + PEMETREXED | 101512213 |
| 160014487 | 160007114 | 1.75 | 59.9 | Adjuvant (A) | 2018-05-30 | 2018-06-15 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 100140775 |
| 160014488 | 160007115 | 1.61 | 83 | null | 2018-02-28 | 2018-03-01 | Trial Unspecified | 01 | null | IPM | 101801726 |